Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Avelumab in AML with MRD
NCT03699384Phase 2Withdrawn
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2018
- Primary completion
- Feb 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in acute myeloid leukemia (AML), sponsored by Memorial Sloan Kettering Cancer Center. Planned start Oct 2018; status: withdrawn.
02
Drugs
avelumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03699384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699384.